AptarGroup (ATR) Q3 2024 earnings summary

Executive summary

• Q3 2024 reported sales grew 2% to $909.3M, with net income up 19% to $100M, driven by strong operational performance and margin improvement in Pharma and Closures, while Beauty faced headwinds from lower tooling and prestige fragrance sales.

• Pharma segment led growth with double-digit increases in proprietary drug delivery systems and royalty revenues, while Closures benefited from food and beverage demand.

• All three segments demonstrated margin improvement, positioning for double-digit full-year adjusted EPS growth.

• Announced new product launches, FDA and European Commission approvals for nasally delivered emergency medicines, and strategic acquisitions including SipNose technology assets and a joint venture in China.

• Board authorized a new $500M share repurchase program and declared a $0.45 per share dividend payable November 14, 2024.

Financial highlights

• Q3 2024 net sales: $909.3M (+2% year-over-year); nine months: $2.74B (+3%).

• Q3 2024 net income: $100M (up 19%); adjusted EPS: $1.49 (up 6%); adjusted EBITDA: $208M (23% margin, up 8%).

• Free cash flow for nine months: $255M, more than doubling year-over-year.

• Operating income for Q3 2024: $138.3M (15.2% margin), up from $119.3M (13.3%) in Q3 2023.

• Gross margin for Q3 2024: 38.6% (up from 36.5% in Q3 2023).

Outlook and guidance

• Q4 2024 adjusted EPS guidance: $1.22–$1.30; full-year adjusted EPS expected at $5.34–$5.42, a double-digit increase over 2023.

• Pharma core sales expected to finish within the 7–11% long-term target range; Closures segment anticipates a strong finish with margin improvements.

• 2024 capital expenditures projected at $280M–$300M; depreciation and amortization at $260M–$270M.

• Q4 2024 expected to deliver top-line growth and a 20–22% effective tax rate.

• Beauty remains challenged by macro conditions but focuses on cost mitigation and efficiency.